Invention:
Biomarkers for neurological disease are lacking. Preliminary data, using an in vitro model of the blood brain barrier has suggested that serum release of tight junction proteins and the associated phosphoproteome may have utility as a biomarker for headache presence (diagnostic), such as migraine, and in therapeutic effect (theragnostic). This invention is directed to a theragnostic for identifying disease state and prediction of tissue degradation so that secondary ailments can be ameliorated.
Background:
Migraine is the most common primary headache disorder and the second most disabling human condition, whose pathogenesis is favored by a combination of genetic, epigenetic, and environmental factors. Migraine presents with reoccurring symptoms such as headache, nausea, dizziness, and sensitivity to stimuli. In recent years, several efforts have been made to identify reliable biomarker(s) useful to monitor disease activity and/or ascertain the response to a specific treatment.
Applications:
- Headache/migraine treatment
- Determine anti-headache treatment efficacy
- Tissue degradation identification
Advantages:
- Biomarker identification
- Both diagnostic and therapeutic approaches
